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129 Chronic infection with Stenotrophomonas maltophilia in patients
with cystic ﬁbrosis in the Copenhagen CF Centre
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Background: An increasing number of CF patients are colonized with the Gram-
negative multiresistant bacterium Stenotrophomonas maltophilia. The clinical con-
sequences of this infection are not known. The purpose of our study was to
assess the effect on lung function and nutritional status (z-score BMI) in patients
chronicailly infected with S. maltophilia.
Methods: All CF patients (278) treated at the CF centre in Copenhagen were
included in the study. Numbers of sputum cultures positive for S. maltophilia
in the period from 1.1.2008 to 31.12.2009 were counted. FEV1% predicted and
BMI z-score were compared in patients with and without chronic S. maltophilia
pulmonary infection.
Results: Eighty-two CF patients (30 %), median age 19 years (range 2−60) had
at least one culture with S. maltophilia. Chronic infection deﬁned as occurrence
of S. maltophilia in >50% of sputum samples or less often when combined with
the presence of elevated levels of precipitating antibodies against S. maltophilia.
During the study period 499/1877 (27%) sputum samples in 82 patients were
positive. Nineteen patients were chronic infected with S. maltophilia. No differences
were found in FEV1% or BMI z-score between patients intermittent colonised
and patients chronic infected: median 82% (27–126) and 79% (35–106) and −0.5
(−3.18–2.01) and 0.07 (−1.89–1.26) respectively.
Conclusion: This cross-sectional study does not show any effect of chronic
S. maltophilia infection on neither FEV1 nor BMI z-score. Longitudinal study
of impact of chronic S. maltophilia infection on decline of clinical condition of
chronically infected patients is needed.
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Background: Mycobacterium abscessus (MA) is increasingly common in CF pa-
tients, with associated increased morbidity. The aims of this study were to determine
the prevalence of MA in our centre, to identify associated clinical factors and to
review the antibiotic regimes used to treat this organism.
Methods: This is an observational study of patients currently attending the West
Midlands Adult CF Centre. In MA +ve patients we obtained: spirometry, BMI,
microbiology, corticosteroid use, CFRD and ABPA status. We also reviewed their
anti-MA treatment.
Results: Of 325 adult CF patients cared for in our centre, 7 have at least 2 conﬁrmed
sputum isolates of MA: 4 male, mean age 19 (range 16−25) yrs, median BMI
19.1 kg/m2. 4 patients have impaired glucose tolerance (IGT) and 3 have CFRD.
All are chronically infected with P. aeruginosa. 6 of 7 patients are on long-term
oral corticosteroids, none have a history of ABPA.
Our current treatment protocol in stable MA +ve patients consists of at least
3 antibiotics used on a continuous basis: 2 oral antibiotics (clarithromycin, doxy-
cycline or moxiﬂoxacin) with nebulised amikacin or meropenem. Exacerbations
are treated with 2 IV antibiotics (tigecycline, meropenem, imipenem, cefoxitin or
amikacin). 4 of 7 patients experienced adverse effects that limited IV treatment,
most commonly nausea with tigecycline. 5 of 7 patients continue to culture MA,
although 2 patients have been culture −ve for at least 12 months.
Discussion: Intravenous antibiotic therapy for MA is associated with signiﬁcant
adverse effects. 6 of 7 of our MA +ve patients have been on long-term oral
corticosteroids and all either have IGT or CFRD.
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Pandoraea spp. are recently described bacteria causing chronic lung colonization in
CF patients. Their pathogenicity is not well known but invasive disease is possible.
We describe a nosocomial outbreak of Pandoraea pulmonicola in our CF center
in 2009. Bacterial strains were analyzed by MALDI-TOF mass spectrometry,
16S rDNA gene sequencing and Pulsed Field Gel Electrophoresis (PFGE).
Pandoraea spp. were found in 6 patients (5 males, 1 female) out of 243 CF patients
attending our center (incidence rate 20.6‰). The source patient was chronically
colonized since 2000. 1 patient was already colonized by P. pulmonicola before
attending our center and is not thought to be part of the outbreak. 4 other patients
(1 female, 3 males) acquired Pandoraea spp. between June and November 2009.
All were chronically colonized with P. aeruginosa (P.a) and 2 with S. aureus (S.a).
All strains were identiﬁed as P. pulmonicola. Preliminary PFGE results evidence
an epidemiological link between strains. All patients had matching hospitalization
periods and had contacts without strict barrier protection. All strains were resis-
tant to colimycin, aminoglycosides, betalactams including imipenem but partially
susceptible to cefotaxime, tigecycline and rifampicin.
This study shows cross transmission of Pandoraea pulmonicola in CF patients with
chronic P.a or S.a infection, pointing out its potential ability to colonize such patients
and the need to reinforce barrier protection and strict bacteriological screening.
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Achromobacter xylosoxidans is an aerobic, non-fermentative, gram-negative bac-
terium found in a variety of natural environments. A. xylosoxidans strains are innate
resistant to many antibiotics and may rapidly develop resistance to virtually all
available antibiotics. A. xylosoxidans is being isolated from cystic ﬁbrosis patients
with increasing frequency, however, the clinical signiﬁcance of A. xylosoxidans
infection and colonisation in CF patients has not been fully elucidated.
A. xylosoxidans was cultured from 16 of 143 (11%) CF patients at Aarhus University
Hospital Skejby during 2009. Five patients had been chronically infected for more
than six years and ﬁve patients had been infected for two to three years. However, six
patients experienced a ﬁrst-time identiﬁcation of A. xylosoxidans in their respiratory
cultures during 2009. Four of the chronically infected patients carry A. xylosoxidans
with the same genotype, as evaluated by Pulsed-Field Gel Electrophoresis. These
patients are known to have had close contact outside the centre. The remaining
patients, including all patients with isolates acquired during 2009, carry unique
genotypes.
